Table 2 Summary of CMV pharyngeal or laryngeal ulceration with HIV infection in the current and previous cases
No. (Ref) | Age, yr | Sex | CD4 cell count (/μL) | HIV RNA (copies/mL) | CMV DNA or CMV antigen | Site | No. of biopsies | Treatment | Treatment period | Outcome | IRIS |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 [3] | 27 | M | NA | NA | NA | P | 1 | GCV | 2 weeks | Improved | NA |
2 [3] | 43 | M | NA | NA | NA | L | 2 | GCV | 2 weeks | Improved | NA |
3 [4] | 36 | M | NA | NA | NA | O,P | 1 | None | NA | Improved | NA |
4 [4] | 42 | M | NA | NA | NA | C,D,E,P | 1 | GCV | 8 weeks | Death | NA |
5 [4] | 45 | M | NA | NA | NA | D,L,O,P | 1 | GCV | NA | Improved | NA |
6 [5] | 33 | F | 2 | 5.5*10^5 | Antigen positive | P | 1 | None | NA | Improved | NA |
Present case | 57 | M | 11 | 3.1*10^5 | Antigen positive | D,P | 5 | GCV,VGCV | 2 weeks | Improved | + |